Ignite Creation Date:
2024-05-06 @ 4:15 PM
Last Modification Date:
2024-10-26 @ 2:06 PM
Study NCT ID:
NCT04920903
Status:
COMPLETED
Last Update Posted:
2022-07-20
First Post:
2021-06-04
Brief Title:
A Single and Multiple Ascending Dose Study of COR588
Sponsor:
Cortexyme Inc
Organization:
Cortexyme Inc
Study Overview
Official Title:
A Phase 1 Randomized Double-Blind Placebo-Controlled First-in-Human Single- and Multiple-Ascending Dose Study Evaluating the Safety Tolerability and Pharmacokinetics of Oral COR588 in Healthy Adult Subjects
Status:
COMPLETED
Status Verified Date:
2022-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The study is a randomized double-blind placebo-controlled single and multiple ascending dose study to assess the safety and tolerability of COR588 HCl in healthy male and female subjects
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
True
Is an FDA AA801 Violation?:
None